Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

isavuconazonium

isavuconazonium
  • Restricted Cresemba -- IV and PO are restricted to ID for use in immunocompromised patients for invasive fungal infection due to aspergillosis, mucormycosis, or if patient cannot tolerate/failed treatment with other agents.
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Cresemba CAPSULE, ORAL 186 mg      
Cresemba POWDER FOR INJECTION, INTRAVENOUS 372 mg      
VIEW MORE Azoles
CLASS
081408
Comments:

Automatic IV to PO conversion approved.

Cresemba is classified as formulary status, restricted to Infectious Disease for use in immunocompromised patients for treatment of invasive fungal infection due to aspergillosis or mucormycosis or in patients that have failed/cannot tolerate other agents.

Reviewed: 26 May 2015

Last updated: Jul. 17, 2024






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved